IVF pregnancy?

Yes 9 (11%)

No 75 (89%)

Known to have BRCA mutation?

Yes 3 (4%)

No 69 (82%)

Missing 12 (14%)

__________________________________________________________________________

Table 2. Presentation at diagnosis

Characteristic Median (IQR*, range) or No of patients (%)

Gestational age at diagnosis (weeks) 25 (16-33, 2 to 40) N= 84 (100%)

<14 18 (21%)

14 - 6 23 (28%)

27 - 36 32 (38%)

37 - 40 5 (6%)

Missing 6 (7%)

Symptoms

Asymptomatic 2 (2%)

Symptomatic 76 (91%)

Missing 6 (7%)

Lump only 50 (60%)

Lump with or without other symptoms 70 (83%)

Pain / tenderness with or without other symptoms 13 (16%)

Skin changes / nipple inversion with or without other symptoms 10 (12%)

Other symptoms 2 (2%)

Clinical size of tumour at diagnosis (mm) 26 (20-40, 7 to 120) N= 84 (100%)

≤ 20 14 (17%)

30 – 50 37 (44%)

> 50 6 (7%)

Missing 27 (32%)

Interval from symptoms to diagnosis (weeks) 3 (2-9, 0 to 56) N= 84 (100%)

0 - 4 45 (53%)

5 - 9 10 (12%)

10 – 14 8 (9%)

15 – 19 1 (1%)

20 – 24 1 (1%)

>24 5 (6%)

Missing 10 (18%)

__________________________________________________________________________

Table 3. Tumour characteristics and staging

Characteristic ER (+) ER (-) Total*

41(49%) 29 (35%) 84 (100%)

Histological grade

1 0 (0%) 0 (0%) 1 (1%)

2 12 (29%) 3 (10%) 15 (18%)

3 25 (60%) 19 (66%) 45 (53%)

N/A 1 (2%) 2 (7%) 4 (5%)

Missing 4 (9%) 5(17%) 19 (23%)

Histological type

Ductal 37 (90%) 23 (79%) 62 (74%)

Lobular 1 (2%) 1 (3%) 3 (4%)

Ductal and lobular 1 (2%) 0 (0%) 1 (1%)

Metaplastic 0 (0%) 1 (3%) 1 (1%)

Poorly differentiated 0 (0%) 2 (7%) 2 (2%)

DCIS 2 (5%) 0 (0%) 2 (2%)

Missing 0 (0%) 2 (7%) 13 (16%)

Distribution of cancer

Localised 26 (63%) 22 (76%) 51 (61%)

Multifocal 11 (27%) 4 (14%) 15 18%)

Missing 4 (10%) 3 (10%) 18 (62%)

PR Status

Positive 23 (56%) 1 (3%) 25 (30%)

Negative 5 (12%) 26 (90%) 31 (37%)

Missing 13 (32%) 2 (7%) 28 (33%)

HER2 Status

Positive 15 (37%) 8 (28%) 24 (28%)

Negative 25 (61%) 20 (69%) 45 (54%)

Missing 1 (2%) 1 (3%) 15 (18%)

Pathological T stage

T1 14 (34%) 6 (21%) 20 (24%)

T2 17 (42%) 11 (38%) 30 (36%)

T3 5 (12%) 6 (21%) 12 (14%)

T4 1 (2%) 2 (7%) 4 (5%)

Missing 4 (10%) 4 (13%) 18 (21%)

N Stage

N0 14 (34%) 10 (35%) 25 (30%)

N1 10 (25%) 5 (17%) 17 (21%)

N2 3 (7%) 4 (14%) 7 (8%)

N3 3 (7%) 4 (14%) 7 (8%)

Missing 11 (27%) 6 (20%) 28 (33%)

M Stage

M0 39 (95%) 26 (90%) 68 (81%)

M1 1 (2%) 2 (7%) 4 (5%)

Missing 1 (2%) 1 (3%) 12 (14%)

__________________________________________________________________________

ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; PR: progesterone receptor.

DCIS: Ductal carcinoma in situ

*ER status unknown for 14 women